- Trial phase
- Approved (Accelerated Approval)
- Time to market
- Already on the market under accelerated approval (since February 2021). The sNDA for traditional approval has a PDUFA goal date around April 2027.
- Why 7/10
- The next hard, dated catalyst is the FDA's PDUFA decision on the sNDA seeking to convert AMONDYS 45 from accelerated to traditional approval. The sNDA was accepted for filing on June 30, 2026, and with standard review (10 months), the PDUFA goal date is approximately April 2027. This is a major binary event for a drug that drives a substantial portion of Sarepta's revenue, though the company also has other programs (Elevidys, DM1/FSHD pipeline).
Watch for the FDA's decision on the sNDA for traditional approval of AMONDYS 45, expected around April 2027 (standard review timeline from the June 30, 2026 acceptance). Approval would remove the overhang from the failed ESSENCE confirmatory trial and solidify the PMO franchise's revenue stream. Denial could threaten the drug's continued marketing and would be a significant negative for SRPT shares.
Price Chart
Executive Summary
AMONDYS 45 (casimersen) is an exon-skipping therapy for Duchenne muscular dystrophy (DMD) patients with mutations amenable to exon 45 skipping. It received FDA accelerated approval in February 2021 based on surrogate dystrophin production endpoints. In November 2025, the confirmatory Phase 3 ESSENCE trial failed to meet its primary endpoint, yet Sarepta submitted sNDAs seeking conversion to traditional approval, which the FDA accepted for filing in June 2026. The drug is already on the market and generated significant revenue as part of Sarepta's PMO franchise ($240.3M in Q3 2026). The next major catalyst is the FDA's PDUFA decision on the sNDA, expected around April 2027 under standard review. The outcome is uncertain given the failed confirmatory trial, making this a high-stakes binary event for a drug that drives a large portion of Sarepta's revenue.
How It Works
AMONDYS 45 (casimersen) is an exon-skipping therapy for Duchenne muscular dystrophy (DMD), a genetic disease that causes progressive muscle degeneration. It is a synthetic molecule designed to 'skip over' a specific faulty section (exon 45) of the dystrophin gene during protein production, allowing the body to produce a shortened but still functional version of the dystrophin protein that DMD patients lack. It is administered as a weekly intravenous infusion.
Trial Status
AMONDYS 45 received FDA accelerated approval on February 25, 2021. The confirmatory Phase 3 ESSENCE study (testing both AMONDYS 45 and VYONDYS 53) failed to meet its primary endpoint, announced in November 2025. Despite this, Sarepta submitted sNDAs seeking conversion to traditional approval, which the FDA accepted for filing on June 30, 2026 under standard review.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision on sNDA for traditional approval of AMONDYS 45, expected around April 2027
- Q4 2026 earnings report and 2027 revenue guidance (early 2027)
- Multiple ascending dose data readouts for SRP-1003 (DM1) and SRP-1001 (FSHD) expected by end of 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report